FOR IMMEDIATE RELEASE
Novis Pharmaceuticals Announces John W. Kilgour as
Executive Vice- President of Sales & Marketing
MIAMI, FLORIDA, August 11, 2008 - Novis Pharmaceuticals, a leading distributor of
biotherapeutic products to healthcare providers, announced today that John W. Kilgour
has been named Executive Vice President of Sales and Marketing. John is a healthcare
professional with thirty-five years of business and management experience in both
pharmaceutical and medical/surgical supply chain distribution.
Recently retired from Cardinal Health, John held positions of increasing responsibility for
more than 35 years and most recently served as Vice President of Sales in Cardinal’s
Pharmaceutical Supply Chain Program. Primary responsibilities included sales to
Integrated Delivery Networks (IDNs) and particular emphasis on resource leadership,
coaching and developing Cardinal’s related sales groups. Other key positions within
Cardinal Health included sales management to national and regional Group Purchasing
Organizations (GPOs) as well as managing pharmaceutical and medical supply sales and
marketing initiatives for the acute care and managed care business segments.
Tom Burke, President and CEO of Novis Pharmaceuticals, said, “ John will be a great
mentor and teacher for our employees and an even better advocate for our customers. He
has established longstanding, solid relationships and has a reputation of going the extra
mile for clients, employees, and especially patients. His knowledge of the industry is
second to none and we consider ourselves very fortunate to have him as part of the Novis
team.”
“I am excited to be here, “ added John Kilgour. “ I am very impressed with Novis’ core
competencies and the really exceptional people who work here. This is a talented,
enthusiastic and energetic group dedicated to exceeding customer expectations while
meeting important patient need. Simply stated, the “customer relationship” and
“dedication to patient need” is paramount in all that we do.”
^ back to top
Novis Pharmaceuticals Hires Lisa Lopez
Human Resources Professional Brings Diverse Expertise
MIAMI, FLORIDA, December 10, 2007 - Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers, is pleased to announce that Lisa Lopez has joined the company as Vice President of Human Resources. Ms. Lopez was most recently Human Resources Director at Cordis Corporation, a Johnson & Johnson Company. Her 17-year career began in Human Resources shortly after graduating from Florida International University (FIU). She has held various Human Resources roles of increasing responsibilities at Siemens, The Dow Chemical Company and Ryder Systems, Inc. Ms. Lopez also earned an MBA from FIU.
Tom Burke, President and CEO of Novis Pharmaceuticals, said, “Lisa brings a diverse background in Human Resources including recruitment, compensation, benefits, talent development, employee retention, training, and compliance. We have aggressive growth goals and a commitment to our customers to provide industry-leading standards of excellence. We know it is the quality of our people that defines who we are as an organization and Lisa’s expertise will be invaluable to our future success.”
“I am excited to join Novis Pharmaceuticals,” added Ms. Lopez. “I have been impressed with the people and their passion for healthcare and delivering extraordinary service to our customers and partners. I look forward to helping build the Novis Pharmaceuticals of the future by acquiring, developing and retaining the top talent in the industry.”
^ back to top
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
Industry Veteran Combines Expertise with Passion for Healthcare
MIAMI, FLORIDA, November 15, 2007 - Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers funded by MTS Health Investors and Oaktree Capital Management, L.P., announced today the appointment of Thomas E. Burke III to the position of President and CEO. Tom brings over 30 years of distribution experience to Novis Pharmaceuticals, with extensive functional expertise in sales, sales management, operations and the management and development of people.
As the Group Vice-President of Cardinal Health, Integrated Provider Solutions, Tom had Northeast responsibility for five businesses: Distribution, Laboratory, Manufactured Products, Pyxis Supply and Presource which generated $1.4 billion in revenue. He also held several executive level positions in other Cardinal Health companies, including serving as President of the Southeast and the Northeast Regions of Cardinal Health, Medical Products and Services, each with revenue in excess of $1.3 billion and consisting of seven distribution facilities. In addition, Tom was responsible for a two-facility region that represented $3.1 billion in pharmaceutical sales for Cardinal Distribution/Aurora, Illinois Division when he held the position of Regional Vice President.
Jay J. Levin, Executive Chairman of Novis Pharmaceuticals, said, “Novis is committed to providing industry-leading standards of quality and exceptional service to our customers. We were looking for an innovative and visionary leader who not only had the depth of functional expertise to grow the business and to develop our people, but also the personal integrity and character to build sustainable and mutually-rewarding relationships with our manufacturers, our supply chain partners, and our customers.”
“I am honored to have worked my entire career in an industry that makes a difference in patients’ lives,” added Tom Burke. “In order for Novis Pharmaceuticals to succeed, we know we must deliver flawlessly every time. We know that we can save a life every time one of our products is used. There is no room for error.”
^ back to top
MTS, OAKTREE ANNOUNCE THE FORMATION OF NOVIS PHARMACEUTICALS, LLC
April 10, 2007, New York, NY – MTS Health Investors, LLC (“MTS”) and Oaktree
Capital Management, LLC (“Oaktree”) today announced the formation of Novis
Pharmaceuticals, LLC, a new company that will distribute biotherapeutic products to
healthcare providers. Funds under the management of MTS and Oaktree formed Novis
Pharmaceuticals and provided equity capital for the new company and its acquisition of
certain assets of a specialty drug distributor.
This transaction positions Novis Pharmaceuticals as a leading national distributor of
some of the world’s leading plasma-derived products such as albumin, immune globulin,
hyperimmunes and anti-hemophilic Factors VII, VIII and IX. Hospitals, home infusion
therapy companies and other healthcare providers use these biotherapeutics to treat
trauma, autoimmune conditions, immune deficiencies, infectious diseases, bleeding
disorders, and other life-threatening conditions. Terms of the transaction were not
disclosed.
Based in Miami, FL, Novis Pharmaceuticals has a network of five strategically-located
distribution points across the U.S. and Puerto Rico. In addition, the company’s 50-person
sales force is among the industry’s leading sellers of biotherapeutic products and
possesses broad and long-standing customer relationships.
Jay J. Levin, 46, an Operating Partner at MTS, has joined Novis Pharmaceuticals as
Executive Chairman. Previously he was President of Magellan Health Services,
Executive Vice President of Oxford Health Plans and Chief Executive Officer of PPOM.
“Novis is committed to providing industry-leading standards of quality and exceptional
service to its customers,” Mr. Levin said. “To meet customer and patient needs, we will
offer same-day delivery of medications and 24/7 customer service.”
Oliver T. Moses, Managing Director of MTS Health Investors said, “MTS and Oaktree
welcome the opportunity to provide financial backing for this premier distributor in a
growing industry segment. We are eager to support Novis’s commitment to be the
industry’s most reliable and trusted source for quality biotherapeutics.”
The market for plasma-derived products is estimated to generate approximately $2 billion
in annual sales in the U.S., and approximately $6 billion worldwide. The market is
expected to maintain its recent growth rate of approximately 7% a year, driven by new
clinical applications and the aging population.
 read more...
^ back to top
|
